Redhill Biopharma Announces Promising Opaganib Findings for Neuroblastoma and Triple-Negative Breast Cancer
- Redhill Biopharma reports positive preclinical results for opaganib in treating neuroblastoma and triple-negative breast cancer.
- The findings indicate that opaganib may enhance effectiveness of existing combination chemotherapy.
- These results suggest potential improvements in patient outcomes with the use of opaganib.
Redhill Biopharma Ltd. reports significant preclinical findings regarding its drug opaganib, presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The studies suggest that opaganib could function as a valuable add-on therapy for treating neuroblastoma (NB) and triple-negative breast cancer (TNBC). These promising results support Redhill's ongoing commitment to addressing critical unmet medical needs in oncology.
Opaganib Demonstrates Enhanced Effectiveness in Combination Chemotherapy
Conducted by researchers from Penn State University and Apogee Biotechnology, the studies, funded by the Beat Childhood Cancer Foundation and Four Diamonds, reveal that opaganib can significantly enhance the efficacy of existing chemotherapy regimens. Specifically, it enhances the performance of oxaliplatin and doxorubicin (OXDOX) in high-risk neuroblastoma patients. A key finding shows that opaganib destabilizes n-Myc, an oncogenic driver, potentially increasing programmed cell death through heightened ceramide production.
Further insights shared by Colette Worcester from the University of Kansas indicate that pre-treatment with opaganib may augment the effects of low-dose diABZI, which could enhance anti-tumor immunity through STING-mediated pathways. This could be particularly advantageous for TNBC patients, who typically face a poor prognosis among subtypes of breast cancer. Given the established safety and efficacy profiles of opaganib, the findings underscore the drug's potential to affect various oncology conditions.
Redhill Biopharma's Ongoing Commitment to Oncology
Dr. Mark Levitt, RedHill’s Chief Scientific Officer, emphasizes the significance of these findings, indicating that they may improve therapeutic outcomes for both pediatric neuroblastoma and aggressive forms of breast cancer. As Redhill continues to expand its research and development efforts, the company aims to leverage opaganib's capabilities for better treatment solutions in oncology.
A Step Forward in Oncology
Redhill Biopharma's recent developments represent a crucial advancement within the oncology sector, targeting unmet medical needs and aiming to improve patient care. With opaganib at the forefront, Redhill is not only enhancing treatment options for patients but also contributing to a broader understanding of therapeutic possibilities in challenging diseases.